Savara is an orphan lung disease company. Savara’s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP and in Phase 2a development for nontuberculous mycobacteria, or NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA lung infection in cystic fibrosis, or CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Molgradex for PAP
Molgradex is the first treatment being developed for inhalation of GM-CSF for the treatment of patients suffering from a rare respiratory disease called pulmonary alveolar proteinosis (PAP).
AeroVanc for CF
AeroVanc is the first inhaled antibiotic being developed to address the growing problem of chronic methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF).